Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers

Journal of Clinical Pharmacology

Volumn 47, Issue 7, 2007, Pages 877-889

  Zong, Jian ^b   Chittick, Gregory E ^b   Wang, Laurene H ^a   Hui, James ^b   Begley, John A ^b   Blum, M Robert ^b  

^a IntellPharma LLC   (United States)

^b GILEAD SCIENCES INC   (United States)

Author keywords

Antivirals; Drug interactions; Emtricitabine; Famciclovir; Nucleoside reverse transcriptase inhibitor; Nucleosides; Penciclovir; Pharmacokinetics; Stavudine; Zidovudine

Indexed keywords

EMTRICITABINE; FAMCICLOVIR; PENCICLOVIR; STAVUDINE; ZIDOVUDINE; ZIDOVUDINE GLUCURONIDE; 2 AMINOPURINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; SINGLE DRUG DOSE; URINARY EXCRETION; ADOLESCENT; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG COMBINATION; DRUG INTERACTION; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

2-AMINOPURINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DEOXYCYTIDINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 34548024165     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007300808     Document Type: Article

References (11)

1. Gilead Sciences. Emtriva® (emtricitabine) capsules prescribing information. Available at: http://www.gilead.com/pdf/emtriva-pi.pdf. Accessed October 26, 2006.
2. 2. Bang LM, Scott LJ. Emtricitabine: an antiretroviral agent for HIV infection. Drugs. 2003;63:2413-2424. (Pubitemid 37392907)
3. Rana KZ, Dudley MN. Clinical pharmacokinetics of stavudine. Clin Pharmacokinet. 1997;33:276-284.
4. Blum MR, Liao SHT, Good SS, deMiranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med. 1988; 85(suppl 2A):189-194.
5. Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet. 1996;31:1-8.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;6:31-41.
7. Wang LH, Blum MR, Begley J, et al. Lack of significant pharmacokinetic interactions between emtricitabine and other nucleoside antivirals in healthy volunteers (Abstract A-505). Paper presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 2001; Chicago, 111.
8. Blum MR, Chittick GE, Begley J, Zong J. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol. In press.
9. Saag MS, Calm P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviralnaive patients: a randomized trial. JAMA. 2004;292:180-189.
10. 10. Benson CA, van de Horst C, LaMarca A, et al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS. 2004;18:2269-2276. (Pubitemid 39620219)
11. 11. Molina JM, Journot V, Morand-Joubert L, et al. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis. 2005;191:830-839. (Pubitemid 40349796)